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Summary
Background.  —  In  patients  with  coronary  artery  disease  (CAD),  non-optimal  use  of  evidence-
based medications  is  associated  with  an  increased  risk  of  adverse  outcome.
Aims. —  To  assess  the  prevalence  and  correlates  of  non-optimal  secondary  medical  prevention
in patients  with  stable  CAD.
Methods.  —  We  included  4184  consecutive  outpatients  with  stable  CAD.  Treatment  at  inclusion
was classiﬁed  as  optimal/non-optimal  regarding  the  four  major  classes  of  secondary  prevention
drugs: antithrombotics;  statins;  angiotensin-converting  enzyme  (ACE)  inhibitors  or  angiotensin
II receptor  blockers  (ARBs);  and  beta-blockers.  For  each  treatment,  the  prescription  was  consid-
ered non-optimal  if  the  drug  was  missing  despite  a  class  IA  indication  according  to  international
guidelines.  To  assess  the  information  globally,  non-optimal  secondary  prevention  was  deﬁned
as at  least  one  major  treatment  missing.
Results.  —  The  proportions  of  patients  with  non-optimal  treatment  were  0.7%,  7.8%,  12.9%
and 10.3%  for  antithrombotics,  statins,  ACE  inhibitors/ARBs  and  beta-blockers,  respectively.
Non-optimal  secondary  medical  prevention  was  observed  in  16.8%  of  cases.  By  multivariable
analysis,  the  correlates  of  non-optimal  secondary  medical  prevention  were  long  time  interval
since last  coronary  event  (P  <  0.0001),  older  age  (P  <  0.0001),  diabetes  mellitus  (P  <  0.0001),
hypertension  (P  <  0.0001),  no  history  of  myocardial  infarction  (P  =  0.001),  no  history  of  coronary
revascularization  (P  =  0.013)  and  low  glomerular  ﬁltration  rate  (P  =  0.042).
Conclusions.  —  Although  most  patients  with  stable  CAD  are  receiving  evidence-based  medica-
tions according  to  guidelines,  there  remain  subgroups  at  higher  risk  of  non-optimal  treatment.
In particular,  it  might  be  feasible  to  improve  prevention  by  focusing  on  patients  in  whom  a  long
time has  elapsed  since  the  last  coronary  event.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  En  cas  de  maladie  coronaire,  l’utilisation  non  optimale  des  thérapeutiques  de
prévention  secondaire  est  associée  à  une  augmentation  du  risque  d’événements  cliniques.
Objectif.  —  Analyser  la  prévalence  et  les  déterminants  d’une  prévention  secondaire  non  opti-
male en  cas  de  maladie  coronaire  stable.
Méthodes.  —  Nous  avons  inclus  4184  patients  ambulatoires  présentant  une  maladie  coronaire
stable. Le  traitement  à  l’inclusion  a  été  déﬁni  comme  optimal/non  optimal  pour  les  4  grandes
classes thérapeutiques  de  prévention  secondaire  :  antithrombotiques,  statines,  inhibiteurs  de
l’enzyme  de  conversion  (IEC)  ou  antagonistes  du  récepteur  de  l’angiotensine  II  (ARAII),  et  ß-
bloquants.  Pour  chaque  traitement,  la  prescription  a  été  considérée  comme  non  optimale  si  la
thérapeutique  était  manquante  en  dépit  d’une  indication  de  classe  IA  dans  les  recommanda-
tions internationales.  Pour  analyser  l’information  globalement,  une  prévention  secondaire  non
optimale  a  été  déﬁnie  comme  ≥  1  traitement  majeur  manquant.
Résultats.  —  Le  pourcentage  de  patients  avec  un  traitement  non  optimal  était  de  0,7  %,  7,8  %,
12,9 %  et  10,3  %  pour  les  antithrombotiques,  statines,  IEC/ARAII  et  ß-bloquants,  respectivement.
Une prévention  secondaire  non  optimale  a  été  observée  dans  16,8  %  des  cas.  En  analyse  mul-
tivariée, les  facteurs  associés  à  une  prévention  secondaire  non  optimale  étaient  un  délai  long
depuis le  dernier  événement  coronarien  (p  <  0,0001),  l’âge  (p  <  0,0001),  un  diabète  (p  <  0,0001),
une hypertension  artérielle  (p  <  0,0001),  l’absence  d’antécédent  d’infarctus  (p  =  0,001)  ou  de
revascularisation  myocardique  (p  =  0,013)  et  une  clairance  de  la  créatinine  diminuée  (p  =  0,042).
Conclusion.  —  Bien  que  la  plupart  des  patients  avec  maladie  coronaire  stable  rec¸oivent  un
traitement  de  prévention  secondaire  en  accord  avec  les  recommandations,  certains  sous-
groupes demeurent  à  risque  de  traitement  non  optimal.  La  prévention  pourrait  en  particulier
être améliorée  en  ciblant  les  patients  qui  ont  un  délai  long  depuis  le  dernier  événement
coronarien.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ntroduction
he  appropriate  use  of  evidence-based  secondary  pre-
ention  treatments  is  of  greatest  importance  for  the
anagement  of  patients  with  stable  coronary  artery  disease
CAD)  [1,2].  Observational  studies  have  associated  non-
ptimal  secondary  medical  prevention  with  an  increased  risk
f  adverse  clinical  outcomes,  including  all-cause  mortality
nd  cardiovascular  mortality  [3,4].  There  is,  however,  rel-
tively  little  contemporary  information  on  the  long-term
se  of  evidence-based  medications  in  patients  with  stable
AD.  In  addition,  although  several  studies  have  suggested
hat  factors  such  as  age,  race/ethnicity  or  practice  site
ay  be  involved  [3,5,6],  the  determinants  of  non-optimal
econdary  medical  prevention  in  patients  with  stable  CAD
i.e.  at  a  distance  from  any  acute  event)  are  not  well
nown.  Such  information  could  be  of  importance,  as  it
ight  help  to  identify  the  subgroup(s)  who  may  beneﬁt  the
ost  from  targeted  interventions  to  improve  prevention.
he  present  study  was  therefore  designed  with  two  speciﬁc
ims:  to  assess  the  prevalence  of  non-optimal  secondary
edical  prevention  in  a  recent  cohort  of  outpatients  with
table  CAD;  and  to  analyse  the  correlates  of  non-optimal
revention.
ethods
tudy population
he  CORONOR  (Suivi  d’une  cohorte  de  patients  COROnariens
tables  en  région  NORd-pas-de-Calais)  study  was  a  multi-
entre  study  that  enrolled  4184  consecutive  outpatients
ith  stable  CAD  between  February  2010  and  April  2011  [7].
atients  were  enrolled  by  50  cardiologists  from  the  Region
ord  Pas-de-Calais  in  France.  Participating  physicians  were
elected  on  the  basis  of  geographic  distribution,  to  provide
 representative  sample  of  current  cardiology  practice  in
niversity,  non-university  and  private  centres  in  the  area.
atients  were  considered  eligible  if  they  had  evidence  of
AD  deﬁned  by  the  presence  of  at  least  one  of  the  following:
revious  myocardial  infarction  (MI)  (>  1  year  ago);  previous
oronary  revascularization  (>  1  year  ago);  and  obstruction
f  ≥  50%  of  the  luminal  diameter  of  at  least  one  native  ves-
el  on  coronary  angiography.  The  sole  exclusion  criterion  was
ospitalisation  for  MI  or  coronary  revascularization  within
he  last  year.  To  ensure  the  population  was  representative
f  the  spectrum  of  patients  with  stable  CAD,  individuals
ith  other  cardiovascular  or  non-cardiovascular  illnesses  or
o-morbidities  were  included.
ata collection
t  the  initial  visit,  the  attending  physicians  prospectively
ompleted  the  case  record  forms,  which  contained  infor-
ation  regarding  demographic  and  clinical  details  of  the
atients,  including  the  usual  cardiovascular  risk  factors  and
reatments.  During  the  outpatient  visit,  the  investigators
eviewed  the  current  drug  treatment  and  entered  all  pre-
cribed  drugs  in  the  case  record  form.  If  any  change  was
eeded  at  the  time  of  the  outpatient  visit,  it  was  taken  into
ccount  for  the  present  analysis.
i
e
c
oT.  Meurice  et  al.
se of major secondary prevention therapies
or  each  patient,  the  treatment  at  inclusion  was  clas-
iﬁed  as  optimal/non-optimal  regarding  the  four  major
lasses  of  secondary  prevention  drugs,  according  to  the
nternational  guidelines  available  at  the  time  of  inclu-
ion  [1,2]. Optimal  antithrombotic  therapy  was  deﬁned  as
he  prescription  of  aspirin  or  clopidogrel  or  a vitamin  K
ntagonist.  Optimal  statin  treatment  was  deﬁned  as  the
rescription  of  a statin  for  all  patients.  Optimal  renin-
ngiotensin  system  antagonist  treatment  was  deﬁned  as
he  prescription  of  an  angiotensin-converting  enzyme  (ACE)
nhibitor  or  an  angiotensin  II  receptor  blocker  (ARB)  in
he  subgroup  (n  =  3335)  with  a  class  IA  indication  for  ACE
nhibitors  (i.e.  patients  with  a  left  ventricular  ejection
raction  [LVEF]  ≤  40%,  diabetes  mellitus  or  hypertension).
ptimal  beta-blocker  treatment  was  deﬁned  as  the  pre-
cription  of  a  beta-blocker  in  the  subgroup  (n  =  378)  with  a
lass  IA  indication  for  beta-blockers  (i.e.  patients  with  an
VEF  ≤  40%).  To  assess  the  information  globally,  the  num-
er  of  major  treatments  missing  (as  deﬁned  above)  was
alculated.  Non-optimal  secondary  medical  prevention  was
eﬁned  as  at  least  one  major  treatment  missing.
tatistical analysis
ontinuous  variables  are  described  as  means  ±  standard
eviations  or  as  medians  with  25th  and  75th  percentiles.
ategorical  variables  are  presented  as  absolute  numbers  and
ercentages.  The  last  coronary  event  was  deﬁned  as  the
ost  recent  MI  or  coronary  revascularization.  For  patients
ith  no  history  of  MI  or  coronary  revascularization  (n  =  212),
he  date  of  CAD  diagnosis  was  used  instead  of  the  last
oronary  event.  We  analysed  the  correlates  of  non-optimal
econdary  medical  prevention.  Univariate  analysis  was  per-
ormed  using  the  Chi2 test  or  Fisher’s  test  for  categorical
ariables,  and  Student’s  unpaired  t  test  for  continuous  varia-
les,  as  appropriate.  Multivariable  analysis  was  performed
sing  logistic  regression.  Odds  ratios  (ORs)  and  correspond-
ng  95%  conﬁdence  intervals  (CIs)  were  calculated.  Variables
ith  a P  value  <  0.05  in  univariate  analysis  were  entered  into
he  ﬁnal  multivariable  model.  Colinearity  was  excluded  by
eans  of  a  correlation  matrix  between  candidate  predic-
ors.  All  statistical  analyses  were  performed  with  STATA®
.2  software  (STATA  Corporation,  College  Station,  TX,  USA).
tatistical  signiﬁcance  was  assumed  at  a  P  value  <  0.05.
esults
he  baseline  characteristics  of  the  patients  included  in  the
ORONOR  study  have  been  reported  previously  [7,8].  As
hown  in  Table  1,  the  mean  age  was  66.9  ±  11.6  years  and
2.3%  were  women.  Sixty-two  percent  of  the  patients  had
 history  of  MI;  the  median  time  between  last  MI  and  inclu-
ion  was  5  years  (range,  1—34  years).  Eighty-six  percent  of
he  patients  had  a  history  of  coronary  revascularization;  the
edian  time  interval  between  the  last  revascularization  andnclusion  was  4  years  (range,  1—33  years).  The  median  time
lapsed  since  last  coronary  event  (MI  or  coronary  revas-
ularization)  was  5  years  (range,  1—33  years).  Only  7.3%
f  the  patients  were  symptomatic  (angina)  at  inclusion.
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Table  1  Baseline  characteristics  and  treatment  at
inclusion  (n  =  4184).
Age  (years)  66.9  ±  11.6
Women  22.3
Diabetes  mellitus  31.0
History  of  hypertension  60.2
History  of  myocardial  infarction  62.4
Multivessel  coronary  artery  disease  57.8
History  of  coronary  revascularization  85.9
History  of  coronary  stent  implantation  68.9
History  of  CABG 21.3
History  of  hospitalization  for
decompensated  HF
7.5
Left  ventricular  ejection  fraction  (%)  57.5  ±  10.8
Estimated  GFR  (mL/min/1.73  m2)  79  [63—93]
Treatment  at  inclusion
Aspirin  77.0
Clopidogrel  40.2
Vitamin  K  antagonist 11.1
Any  antithrombotic  drug 99.3
ACE  inhibitor 59.3
ARB  24.0
ACE  inhibitor  or  ARB 81.9
Beta-blocker  79.4
Statin  92.2
Data are mean ± standard deviation, percentage or median
[25th—75th percentiles]. ACE: angiotensin-converting enzyme;
ARB: angiotensin II receptor antagonist; CABG: coronary artery
Figure 1. Non-optimal secondary medical prevention in patients
with stable coronary artery disease. (A) Proportion with non-optimal
treatment for each of the four major classes of secondary pre-
vention drugs: antithrombotics (aspirin or clopidogrel or a vitamin
K antagonist); statins; angiotensin-converting enzyme inhibitors
(ACE inhibitors) or angiotensin II receptor blockers (ARBs); and
beta-blockers. The numbers of patients with non-optimal treat-
ment are shown in red. The percentage indicates the value with
respect to the number of patients with a class IA indication
for the given medication, which is shown by the entire column.
(B) Distribution of the 4184 patients included in the CORONOR
study, according to the number of major treatments (antithrom-
b
nbypass graft; HF: heart failure; GFR: glomerular ﬁltration rate.
Overall,  there  was  a  wide  prescription  of  secondary  preven-
tion  medications  (antithrombotics,  99.3%;  statins,  92.2%;
ACE  inhibitors/ARBs,  81.9%;  beta-blockers,  79.4%).
Fig.  1A  shows  the  proportions  of  patients  with  major
treatment  missing  despite  a  class  IA  indication  according  to
guidelines.  The  numbers  were  29  (0.7%)  for  antithrombotics,
327  (7.8%)  for  statins,  381  (12.9%)  for  ACE  inhibitors/ARBs,
and  39  (10.3%)  for  beta-blockers.  Most  patients  (83.2%)  had
optimal  secondary  medical  prevention.  Only  16.8%  (n  =  701)
of  the  patients  had  non-optimal  secondary  medical  preven-
tion  (at  least  one  major  treatment  missing);  among  these,
most  had  only  a  single  treatment  missing  (Fig.  1B).
The  correlates  of  non-optimal  secondary  medical  pre-
vention  are  shown  in  Table  2.  By  multivariable  analysis,
the  patients  with  non-optimal  secondary  medical  preven-
tion  were  older,  more  frequently  had  a  history  of  diabetes
mellitus  or  hypertension,  less  frequently  had  a  history  of
MI  or  coronary  revascularization  and  had  lower  estimated
glomerular  ﬁltration  rate.  The  patients  with  non-optimal
secondary  medical  prevention  also  had  a  longer  time  interval
since  last  coronary  event.  The  effect  on  secondary  medical
prevention  of  the  time  elapsed  since  last  coronary  event  is
illustrated  in  Fig.  2.Discussion
In  patients  with  CAD,  substantial  improvements  have
been  made  in  the  prescription  of  secondary  prevention
m
[
b
fotics, statins, ACE inhibitors or ARBs, beta-blockers) missing. N:
umber.edications  at  hospital  discharge  after  an  acute  event
9—12].  However,  the  long-term  outpatient  use  of  evidence-
ased  medications  has  been  less  documented.  In  a  report
rom  the  Duke  Databank  forCardiovascular  Disease  for  year
344  T.  Meurice  et  al.
Table  2  Correlates  of  non-optimal  secondary  medical  prevention  in  patients  with  stable  coronary  artery  disease.
Variable  Optimal  secondary
medical  prevention
(n  =  3483)
Non-optimal  secondary
medical  prevention
(n  =  701)
Univariate
P  value
Multivariable
P  value
Age  (years)  66.2  ±  11.6  70.5  ±  10.8  <  0.0001  <  0.0001
Women  20.9  29  <  0.0001  0.059
Diabetes  mellitus  29.3  39.2  <  0.0001  <  0.0001
History  of  hypertension 57.7  72.9  <  0.0001  <  0.0001
History  of  myocardial  infarction 64  54.8  <  0.0001 0.001
History  of  stroke 7.2  8.6  0.209  —
Multivessel  CAD  57.8  57.8  0.966  —
History  of  coronary  revascularization  86.8  81.5  <  0.0001  0.013
History  of  coronary  stent  implantation  70.4  61.3  <  0.0001  —
History  of  CABG  21  23  0.243  —
History  of  hospitalization  for
decompensated  HF
6.8 11  <  0.0001  0.093
Left  ventricular  ejection  fraction  (%)  57.7  ±  10.5  57  ±  12.2  0.135  —
Estimated  GFR  (mL/min/1.73  m2)  80  [64—94]  73  [56—91]  <  0.0001  0.042
Time  since  last  coronary  event  (years)  4  [2—8]  6 [3—10]  <  0.0001  <  0.0001
Data are mean ± standard deviation, percentage or median [25th—75th percentiles]. CAD: coronary artery disease; CABG: coronary
artery bypass graft; HF: heart failure; GFR: glomerular ﬁltration rate.
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n002  [3],  83%  of  the  patients  reported  aspirin  use,  63%
eported  lipid-lowering  therapy  use,  61%  reported  beta-
locker  use,  and  39%  reported  use  of  all  three  medications.
n  the  international  REACH  (Reduction  of  Atherothrombosis
or  Continued  Health)  registry  [4],  85%  reported  antiplatelet
se,  73%  reported  lipid-lowering  therapy  use  and  63%
eported  beta-blocker  use.  In  the  present  study,  in  a  more
ontemporary  setting,  we  observed  higher  prescription  rates
f  secondary  prevention  medications  in  patients  with  sta-
le  CAD,  a  ﬁgure  similar  to  that  reported  recently  in  the
LARIFY  registry  [13].  We  attempted  to  reﬁne  the  analy-
is  by  deﬁning  non-optimal  secondary  medical  prevention
ccording  to  recent  guidelines.  Indeed,  although  there  is  a
lass  IA  indication  for  both  antithrombotics  and  statins  in
ll  patients  with  stable  CAD,  the  situation  differs  for  ACE
nhibitors/ARBs  and  beta-blockers.  As  speciﬁed  by  European
nd  American  guidelines  [1,2],  ACE  inhibitors  or  ARBs  should
e  prescribed  in  patients  with  stable  CAD  who  also  have
ypertension,  diabetes  mellitus  or  an  LVEF  ≤  40%.  This  def-
nition  led  to  a  target  population  of  3335  (80%)  patients
aving  an  unequivocal  indication  for  ACE  inhibitors/ARBs.
he  target  population  of  patients  who  currently  have  a
lass  IA  indication  for  beta-blockers  is  much  smaller  (n  =  378
9%]  in  the  present  study).  Although  there  is  no  doubt  that
atients  with  an  LVEF  ≤  40%  should  receive  a  beta-blocker
2,14],  there  is  no  evidence  from  randomized  evaluations
hat  beta-blockers  improve  survival  in  the  rest  of  the  stable
AD  population,  and  observational  studies  with  propensity
core  adjustment  have  provided  discordant  results  [15,16].
ur  data  summarized  in  Fig.  1  show  that,  when  focusing  on
lass  IA  indications,  antithrombotics  were  missing  in  <  1%  of
ases,  while  statins,  ACE  inhibitors/ARBs  and  beta-blockers
ere  each  missing  in  around  10%  of  cases.  This  high  level
f  secondary  medical  prevention  is  illustrated  by  the  fact
w
i
t
dhat  <  20%  of  the  patients  had  at  least  one  major  treatment
issing.
Several  variables  were  associated  with  non-optimal  sec-
ndary  medical  prevention  in  CAD  patients.  As  previously
eported  [3,5], advancing  age  was  associated  with  less
dherence  to  guidelines;  similar  results  have  also  been
eported  in  other  cardiovascular  diseases,  such  as  heart  fail-
re  [17]. The  higher  proportion  of  patients  with  diabetes
ellitus  and/or  hypertension  in  the  group  with  non-optimal
reatment  was,  at  least  in  part,  related  to  the  fact  that,
ccording  to  guidelines,  all  these  patients  should  receive
n  ACE  inhibitor  or  an  ARB;  although  the  proportion  of  dia-
etic  or  hypertensive  patients  receiving  ACE  inhibitors/ARBs
ctually  increased  compared  with  non-diabetic  or  non-
ypertensive  counterparts  (data  not  shown),  the  proportion
ith  respect  to  guidelines  was  lower.  One  new  piece  of
nformation  provided  by  the  present  study  was  the  associa-
ion  of  non-optimal  treatment  with  the  time  elapsed  since
ast  coronary  event.  This  is  concordant  with  the  fact  that
atients  with  a  history  of  MI  and/or  coronary  revasculariza-
ion  had  better  secondary  medical  prevention.  Because  of
he  observational  nature  of  our  study,  we  can  only  specu-
ate  on  plausible  explanations  for  this  ﬁnding.  In  the  case
f  a  long  interval  since  last  coronary  event,  the  motivation
or  a  strict  secondary  prevention  strategy  may  decrease.
his  may  be  reinforced  by  the  fact  that,  as  time  goes  by
fter  an  acute  event,  the  side  effects  of  secondary  pre-
ention  drugs  may  become  more  prevalent.  Finally,  given
he  fact  that  patients  with  a  long  interval  since  last  coro-
ary  event  had  their  therapeutic  regimen  started  at  a  time
hen  secondary  prevention  at  discharge  was  less  stringent,
t  is  also  possible  that  these  patients  missed  the  opportunity
o  receive  an  updated  treatment  when  being  re-evaluated
uring  follow-up.
Non-optimal  secondary  prevention  in  stable  CAD  
Figure 2. Time since last coronary event as a determinant of
non-optimal secondary medical prevention in patients with stable
coronary artery disease. (A) Proportion with non-optimal treat-
ment according to time since last coronary event. (B) Age-adjusted
odds ratios (ORs) and 95% conﬁdence intervals (CIs) for non-optimal
s
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Rsecondary medical prevention. The group with a time since last
coronary event < 3 years was used as the reference.
Study limitations
Several  limitations  must  be  acknowledged.  Firstly,  this  study
focused  on  secondary  prevention  prescription  rates,  and
we  did  not  have  access  to  measurements  of  medication
adherence.  Secondly,  medication  contraindications  were  not
documented  in  our  database;  therefore,  the  proportion  of
patients  who  had  non-optimal  secondary  prevention  because
of  absolute  or  relative  contraindications  is  unknown.  Thirdly,
a  global  deﬁnition  of  non-optimal  secondary  prevention
was  used  for  identifying  correlates;  a  much  larger  sample345
ize  would  be  needed  to  perform  a  drug-per-drug  analysis.
ourthly,  the  fact  that  the  inclusion  was  done  by  cardiolo-
ists  may  overestimate  the  extent  to  which  these  patients
re  managed  in  relation  to  guidelines,  and  the  reality  of
anagement  in  the  community  may  be  worse.  Finally,  these
ata  should  be  interpreted  in  the  context  of  the  French
ealthcare  system,  which  totally  covers  expenditure  for  sec-
ndary  prevention.
onclusions
n  modern  clinical  practice  and  in  a  real-life  setting,  most
atients  with  stable  CAD  are  receiving  evidence-based  med-
cations  according  to  guidelines.  There  remain,  however,
everal  groups  of  patients  with  a  higher  risk  of  non-optimal
reatment.  Our  data  show  that  the  achieved  level  of  sec-
ndary  prevention  decreases  as  the  time  elapsed  since  last
oronary  event  increases.  As  there  is  no  reason  to  believe
hat  these  patients  may  be  at  lower  risk  of  a clinical  event,
t  might  be  warranted  to  improve  prevention  by  focusing  on
his  particular  group.
cknowledgements
his  study  was  supported  by  the  Fédération  Franc¸aise de
ardiologie,  Paris,  France.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
eferences
[1] Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guide-
lines on the management of stable coronary artery disease: The
Task Force on the management of stable coronary artery dis-
ease of the European Society of Cardiology. European Heart
Journal 2013;34:2949—3003.
[2] Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/
ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and
management of patients with stable ischemic heart disease:
a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines,
and the American College of Physicians, American Associa-
tion for Thoracic Surgery, Preventive Cardiovascular Nurses
Association, Society for Cardiovascular Angiography and Inter-
ventions, and Society of Thoracic Surgeons. J Am Coll Cardiol
2012;60:e44—164.
[3] Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence
to evidence-based secondary prevention therapies in coronary
artery disease. Circulation 2006;113:203—12.
[4] Kumbhani DJ, Steg PG, Cannon CP, et al. Adherence to sec-
ondary prevention medications and four-year outcomes in
outpatients with atherosclerosis. Am J Med 2013;126:693—700.[5] Rodriguez F, Cannon CP, Steg PG, et al. Predictors of Long-term
Adherence to Evidence-based Cardiovascular Disease Medica-
tions in Outpatients With Stable Atherothrombotic Disease:
Findings From the REACH Registry. Clin Cardiol 2013;36:721—7.
3[
[
[
[
[
[
[46  
[6] Maddox TM, Chan PS, Spertus JA, et al. Variations in Coro-
nary Artery Disease Secondary Prevention Prescriptions Among
Outpatient Cardiology Practices: Insights From the NCDR
(National Cardiovascular Data Registry). J Am Coll Cardiol
2014;63:539—46.
[7] Bauters C, Deneve M, Tricot O, Meurice T, Lamblin N. Progno-
sis of patients with stable coronary artery disease (from the
CORONOR study). Am J Cardiol 2014;113:1142—5.
[8] Hamon M, Lemesle G, Tricot O, et al. Incidence, source,
determinants, and prognostic impact of major bleeding in out-
patients with stable coronary artery disease. J Am Coll Cardiol
2014;64:1430—6.
[9] Savoye C, Equine O, Tricot O, et al. Left ventricular
remodeling after anterior wall acute myocardial infarc-
tion in modern clinical practice (from the REmodelage
VEntriculaire [REVE] study group). Am J Cardiol 2006;98:
1144—9.
10] Fertin M, Hennache B, Hamon M, et al. Usefulness of serial
assessment of B-type natriuretic peptide, troponin I, and c-
reactive protein to predict left ventricular remodeling after
acute myocardial infarction (from the REVE-2 Study). Am J
Cardiol 2010;106:1410—6.11] Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care
for patients with acute myocardial infarction in the National
Registry of Myocardial Infarction from 1990 to 2006. Am Heart
J 2008;156:1045—55.
[T.  Meurice  et  al.
12] Puymirat E, Simon T, Steg PG, et al. Association of changes in
clinical characteristics and management with improvement in
survival among patients with ST-elevation myocardial infarc-
tion. JAMA 2012;308:998—1006.
13] Danchin N, Ferrieres J, Guenoun M, et al. Management of out-
patients in France with stable coronary artery disease. Findings
from the prospeCtive observational LongitudinAl RegIstry oF
patients with stable coronary arterY disease (CLARIFY) registry.
Arch Cardiovasc Dis 2014;107:452—61.
14] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guide-
lines for the diagnosis and treatment of acute and chronic
heart failure 2012: The Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2012 of the Euro-
pean Society of Cardiology. Developed in collaboration with
the Heart Failure Association (HFA) of the ESC. Eur Heart J
2012;33:1787—847.
15] Bangalore S, Steg G, Deedwania P, et al. ß-blocker use and clin-
ical outcomes in stable outpatients with and without coronary
artery disease. JAMA 2012;308:1340—9.
16] Bauters C, Lemesle G, Meurice T, Tricot O, de Groote P, Lamblin
N. Prognostic impact of ß-blocker use in patients with stable
coronary artery disease. Heart 2014;100:1757—61.17] Juilliere Y, Suty-Selton C, Riant E, et al. Prescription of car-
diovascular drugs in the French ODIN cohort of heart failure
patients according to age and type of chronic heart failure.
Arch Cardiovasc Dis 2014;107:21—32.
